RESUMEN
Background@#and Purpose Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. @*Methods@#We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). @*Results@#There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. @*Conclusions@#During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
RESUMEN
Previous phytochemical analysis of methanolic extract of Acalypha indica L. has indicated the presence of steroid, flavonoid and terpenoid types of compounds. Since these compounds are of pharmacological interest, coupled with the use of this plant in traditional medicine, prompted us to check A. indica L. for possible analgesic and antiinflammatory activities. The methanolic extract of A. indica L. showed statistically significant [P<0.001] analgesic activity in mice in a dose-dependent manner. A sustained and significant [P<0.001] inhibition of carrageenan-induced inflammation of rat paw was observed with 125 mg/kg and 250 mg/kg body weight. The methanolic extract of A. indica L. also demonstrated antiinflammatory effect in a dose-dependent manner. Maximum inhibition by the extract was observed at 250 mg/kg body weight after three hours of ingestion, which was comparable to that of the standard drug phenylbutazone at a dose of 100 mg/kg body weight. The obtained results provide a support for the use of this plant in traditional medicine
Asunto(s)
Animales , Masculino , Femenino , Analgésicos/farmacología , Euphorbiaceae/química , Ratones , RatasRESUMEN
This study was conducted to determine the hospital prevalence, clinical severity and treatment outcome of rotavirus versus non-rotavirus diarrhea in children attending a secondary level children hospital of Bangladesh. Total 601 children aged from 1 month to 5 years with watery diarrhea were enrolled and their stool samples were analyzed by ELISA for rotavirus antigen. Total 601 children aged from 1 month to 5 years with watery diarrhea were enrolled and their stool samples were analyzed by ELISA for rotavirus antigen. Despite high prevalence of Rotavirus diarrhea in Bangladesh, majority of this illness can be managed at home and/or in primary health care centers, since clinical severity and outcome of rotavirus diarrhea remains similar to that of non-rotavirus diarrhea. This message is expected to reduce frequent and sometimes un-necessary referral of diarrhea patients to higher centers thereby saving the working hours of the attending parents as well as disease burden to children hospitals having limited beds against the huge demand